Evidence map›Paper›PMID 33968717›Full record

ArticleFrontiers in oncology2021

miRNA-193a-3p Regulates the AKT2 Pathway to Inhibit the Growth and Promote the Apoptosis of Glioma Cells by Targeting ALKBH5.

Yong Cui, Qi Wang, Jing Lin, Lei Zhang, Chi Zhang, Huairui Chen, Jun Qian, Chun Luo

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Emerging Mutual Regulatory Roles between mInternational journal of molecular sciences · 2023
    Review
  4. Article
  5. Role of m6A writers, erasers and readers in cancer.Experimental hematology & oncology · 2022
    Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yong CuiDepartment of Neurosurgery, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Qi WangDepartment of Neurosurgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Jing LinDepartment of Neurosurgery, Changzheng Hospital of Naval Medical University, Shanghai, China.
Lei ZhangDepartment of Neurosurgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Chi ZhangDepartment of Neurosurgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Huairui ChenDepartment of Neurosurgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Jun QianDepartment of Neurosurgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Chun LuoDepartment of Neurosurgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Tongji Hospital · CNTongji University · CNShanghai Changzheng Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence indicates that microRNA (miR)-193a-3p is involved in the tumor progression of various cancers. However, the biological functions and precise molecular mechanisms of miR-193a-3p in gliomas have not been well documented. Accordingly, this study focused on the tumor suppressor role and molecular mechanisms of miR-193a-3p in glioma cells. miR-193a-3p expression was determined by qRT-PCR in glioma tissues and cell lines. U251 and U87 glioma cells were transfected with a miR-193a-3p mimic. The effects of miR-193a-3p on cell growth and apoptosis were investigated using MTT, colony-forming, and flow cytometry assays. Overexpression of miR-193a-3p in U87 cells also significantly suppressed tumorigenicity and induced apoptosis in the xenograft mouse model. Luciferase assays were conducted to determine if ALKBH5 is a direct target of miR-193a-3p in glioma cells. Immunoprecipitation was used to explore the interaction between ALKBH5 and RAC-serine/threonine-protein kinase 2 (AKT2) in glioma cells. miR-193a-3p was downregulated in glioma tissues and cell lines. miR-193a-3p treatment suppressed proliferation and promoted apoptosis in both U251 and U87 cells. Bioinformatics analysis and luciferase reporter assay identified a novel miR-193a-3p target, ALKBH5. Notably, the antitumor effect of miR-193a-3p transfection in glioma cells may be due to the miR-193a-3p-induced inhibition of AKT2 expression caused by the suppression of ALKBH5 expression. Furthermore, immunoprecipitation indicated that ALKBH5 physically interacted with AKT2 through an RNA-independent mechanism in glioma cells. miR-193a-3p directly targets ALKBH5 to inhibit the growth and promote the apoptosis of glioma cells by suppressing the AKT2 pathway both

Indexed as

ALKBH5apoptosisgliomamiR-193a-3pproliferation

Identifiers

PMID33968717
PMCPMC8103841
OpenAlexW3157244046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.